Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis

Background: Cabozantinib, a multiple kinase inhibitor, was recently approved for patients with previously treated unresectable hepatocellular carcinoma (uHCC). We investigated the real-world safety and efficacy profiles of cabozantinib. Methods: This multicenter retrospective study included 110 pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yeong Hak Bang, Choong-kun Lee, Changhoon Yoo, Hong Jae Chon, Moonki Hong, Beodeul Kang, Hyung-Don Kim, Sook Ryun Park, Won-Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Min-Hee Ryu, Baek-Yeol Ryoo
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publishing 2022-05-01
Edice:Therapeutic Advances in Medical Oncology
On-line přístup:https://doi.org/10.1177/17588359221097934
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky